Generics - Generics

Filter

Current filters:

Generics

Popular Filters

101 to 125 of 1142 results

Advent and Avista acquire UCB’s generics subsidiary Kremers Urban

Advent and Avista acquire UCB’s generics subsidiary Kremers Urban

07-11-2014

Global private equity investors Advent International and Avista Capital Partners have signed an agreement…

BelgiumGenericsKremers Urban PharmaceuticalsMergers & AcquisitionsUCB

FDA revokes tentative approval of Ranbaxy’s generic Nexium and Valcyte

07-11-2014

Indian generics drugmaker Ranbaxy Laboratories revealed in a Bombay Stock Exchange filing that it has…

Anti-viralsAstraZenecaGastro-intestinalsGenericsNexiumPfizerRanbaxy LaboratoriesRegulationSun PharmaceuticalUSAValcyte

Actavis third-qtr sales rocket, but loss posted

Actavis third-qtr sales rocket, but loss posted

05-11-2014

Ireland-headquartered generics drug major Actavis today reported net revenue leapt 83% to $3.7 billion…

ActavisFinancialGenerics

EGA and EBG see EMA latest biosimilars guidance as “important step forward”

EGA and EBG see EMA latest biosimilars guidance as “important step forward”

04-11-2014

The European Generic medicines Association (EGA) and the European Biosimilars Group (EBG), a sector group…

BiosimilarsEuropeGenericsRegulation

New analysis of potential savings from Biosimilars in USA

New analysis of potential savings from Biosimilars in USA

04-11-2014

Introducing competing “biosimilar” versions of complex biologic drugs used to treat illnesses such…

Anti-Arthritics/RheumaticsBiosimilarsFinancialGenericsOncologyRegulationSandozUSA

Mylan third-qtr beats expectations

Mylan third-qtr beats expectations

31-10-2014

US generics drugmaker Mylan reported third-quarter 2014 financial results that beat analysts’ consensus…

FinancialGenericsMylan

Mylan debuts generic Viramune XR in USA

Mylan debuts generic Viramune XR in USA

31-10-2014

US generic drugmaker Mylan said yesterday that it has launched its nevirapine extended-release tablets,…

Anti-viralsBoehringer IngelheimGenericsMarkets & MarketingMylanUSAViramune

Canadian generics group in deal for C$560 million savings over three years

Canadian generics group in deal for C$560 million savings over three years

30-10-2014

Atlantic Canadians will save an estimated C$560 million ($500 million) through an unprecedented three-year…

CanadaGenericsPricing

Dr Reddy’s reports higher sales but downturn in pretax profit

Dr Reddy’s reports higher sales but downturn in pretax profit

29-10-2014

Indian generics drugmaker Dr Reddy’s Laboratories today reported its unaudited consolidated financial…

Dr Reddy's LaboratoriesFinancialGenerics

Polish and European generics groups view opportunities for biosimilars

29-10-2014

The European Biosimilars Group – a sector group of the European Generic medicines Association, together…

BiosimilarsEastern EuropeGenericsMarkets & MarketingPolandPricingRegulation

Favorable court ruling for TMC’s Angiomax patent litigation

28-10-2014

US drugmaker The Medicines Company says that the US District Court for the Northern District of Illinois…

AngiomaxCardio-vascularGenericsMylanThe Medicines CompanyUSA

Pfizer prevails in Sutent patent dispute

Pfizer prevails in Sutent patent dispute

23-10-2014

The US District Court for the District of Delaware has upheld US pharma giant Pfizer’s basic patent…

GenericsLegalMylanOncologyPatentsPfizerSutentUSA

US Appeals Court upholds Lo Loestrin Fe patent

US Appeals Court upholds Lo Loestrin Fe patent

23-10-2014

Ireland-headquartered generics major Actavis confirmed that it has prevailed in a court battle over the…

ActavisAmneal PharmaceuticalsGenericsLegalLo LoestrinLupinPatentsReproductiveUSAWomen's Health

Mylan and Abbott amend terms of their $5.3 billion deal

Mylan and Abbott amend terms of their $5.3 billion deal

23-10-2014

US generic drugmaker Mylan and US drugmaker Abbott Laboratories have revised the pricing terms of their…

AbbottAbbott LaboratoriesGenericsMergers & AcquisitionsUSA

Chinese heparin API market to account for about 80% of global demand; report

Chinese heparin API market to account for about 80% of global demand; report

21-10-2014

It is projected that the heparin active pharmaceutical ingredient (API) in China will achieve an additional…

Cardio-vascularChinaGenericsMarkets & Marketing

Valeant third-qtr profits beat expectations

20-10-2014

Canadian drugmaker Valeant Pharmaceuticals International has posted third-quarter 2014 financial results…

AllerganFinancialGenericsMergers & AcquisitionsValeant Pharmaceuticals International

New report: The myth of high Danish medicine prices

20-10-2014

The price-cap agreements between Lif, the Danish pharmaceutical industry group, and the government help…

DenmarkGenericsPharmaceuticalPricing

Actavis challenges Quillivant XR patent

16-10-2014

Ireland-headquartered generics major Actavis confirmed that it has filed an Abbreviated New Drug Application…

ActavisGenericsLegalNeurologicalPatentsPfizerQuillivantRegulationTris PharmaUSA

Teva’s Copaxone case heard again by US Supreme Court

Teva’s Copaxone case heard again by US Supreme Court

16-10-2014

The patent battle over Israel-based Teva Pharmaceutical Industries’ multiple sclerosis drug Copaxone…

CopaxoneGenericsLaw CrimeLegalMylanNeurologicalTevaUS Supreme CourtUSA

FDA consent decree with Ascend Labs backed by federal judge

FDA consent decree with Ascend Labs backed by federal judge

15-10-2014

A federal judge from the US District Court for the Southern District of Ohio entered a consent decree…

Ascend LaboratoriesGenericsLegalProductionRegulationUSA

Netherlands Pharma market growth held back by govt generics policy

14-10-2014

The Netherlands’ pharmaceutical market value will rise slowly from around $6.7 billion in 2014 to $7.2…

FinancialGenericsHealthcareMarkets & MarketingNetherlands

Stada Arz in-licenses teriparatide, expanding its biosimilars portfolio

Stada Arz in-licenses teriparatide, expanding its biosimilars portfolio

13-10-2014

German generic and branded drugmaker Stada Arzneimittel has in-licensed osteoporosis drug teriparatide,…

Anti-Arthritics/RheumaticsBiosimilarsEli LillyForsteoGenericsLicensingRichter-Helm BioTecSTADA Arzneimittelteriparatide

Growth set to return to CIS by 2015 with Kazakhstan in the lead

Growth set to return to CIS by 2015 with Kazakhstan in the lead

13-10-2014

Growth is set to return to markets in the Commonwealth of Independent States between 2015 and 2019, according…

GenericsKazakhstanMarkets & MarketingPharmaceuticalRussiaUkraine

US Congressmen investigate “staggering price increases” for generic drugs

US Congressmen investigate “staggering price increases” for generic drugs

10-10-2014

Letters have been sent to 14 drug manufacturers, including several major Indian firms, requesting information…

GenericsPoliticsPricingUSA

101 to 125 of 1142 results

Back to top